246 related articles for article (PubMed ID: 35666264)
1. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
[TBL] [Abstract][Full Text] [Related]
2. Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD).
Kumru OS; Bajoria S; Kaur K; Hickey JM; Van Slyke G; Doering J; Berman K; Richardson C; Lien H; Kleanthous H; Mantis NJ; Joshi SB; Volkin DB
Hum Vaccin Immunother; 2023 Aug; 19(2):2264594. PubMed ID: 37932241
[TBL] [Abstract][Full Text] [Related]
3. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Kumru OS; Sanyal M; Friedland N; Hickey JM; Joshi R; Weidenbacher P; Do J; Cheng YC; Kim PS; Joshi SB; Volkin DB
Vaccine; 2023 Oct; 41(44):6502-6513. PubMed ID: 37620203
[TBL] [Abstract][Full Text] [Related]
4. Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018
Bajoria S; Kumru OS; Doering J; Berman K; Slyke GV; Prigodich A; Rodriguez-Aponte SA; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
Vaccines (Basel); 2023 May; 11(6):. PubMed ID: 37376419
[TBL] [Abstract][Full Text] [Related]
5. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Cavazzoni CB; Brook B; Barman S; Chen J; Diray-Arce J; Doss-Gollin S; De Leon M; Prevost-Reilly A; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Sage PT; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
Sci Transl Med; 2022 Jan; 14(629):eabj5305. PubMed ID: 34783582
[TBL] [Abstract][Full Text] [Related]
6. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
7. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern.
Pollet J; Strych U; Chen WH; Versteeg L; Keegan B; Zhan B; Wei J; Liu Z; Lee J; Kundu R; Adhikari R; Poveda C; Jose Villar M; Rani Thimmiraju S; Lopez B; Gillespie PM; Ronca S; Kimata JT; Reers M; Paradkar V; Hotez PJ; Elena Bottazzi M
Vaccine; 2022 Jun; 40(26):3655-3663. PubMed ID: 35568591
[TBL] [Abstract][Full Text] [Related]
8. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.
Pino M; Abid T; Pereira Ribeiro S; Edara VV; Floyd K; Smith JC; Latif MB; Pacheco-Sanchez G; Dutta D; Wang S; Gumber S; Kirejczyk S; Cohen J; Stammen RL; Jean SM; Wood JS; Connor-Stroud F; Pollet J; Chen WH; Wei J; Zhan B; Lee J; Liu Z; Strych U; Shenvi N; Easley K; Weiskopf D; Sette A; Pollara J; Mielke D; Gao H; Eisel N; LaBranche CC; Shen X; Ferrari G; Tomaras GD; Montefiori DC; Sekaly RP; Vanderford TH; Tomai MA; Fox CB; Suthar MS; Kozlowski PA; Hotez PJ; Paiardini M; Bottazzi ME; Kasturi SP
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34266981
[TBL] [Abstract][Full Text] [Related]
9. A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine.
Liu D; An C; Bai Y; Li K; Liu J; Wang Q; He Q; Song Z; Zhang J; Song L; Cui B; Mao Q; Jiang W; Liang Z
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146661
[TBL] [Abstract][Full Text] [Related]
10. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
[TBL] [Abstract][Full Text] [Related]
11. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity.
Nanishi E; Borriello F; O'Meara TR; McGrath ME; Saito Y; Haupt RE; Seo HS; van Haren SD; Brook B; Chen J; Diray-Arce J; Doss-Gollin S; Leon M; Chew K; Menon M; Song K; Xu AZ; Caradonna TM; Feldman J; Hauser BM; Schmidt AG; Sherman AC; Baden LR; Ernst RK; Dillen C; Weston SM; Johnson RM; Hammond HL; Mayer R; Burke A; Bottazzi ME; Hotez PJ; Strych U; Chang A; Yu J; Barouch DH; Dhe-Paganon S; Zanoni I; Ozonoff A; Frieman MB; Levy O; Dowling DJ
bioRxiv; 2021 May; ():. PubMed ID: 34031655
[TBL] [Abstract][Full Text] [Related]
12. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
14. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
15. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
16. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19.
Kuo TY; Lin MY; Coffman RL; Campbell JD; Traquina P; Lin YJ; Liu LT; Cheng J; Wu YC; Wu CC; Tang WH; Huang CG; Tsao KC; Chen C
Sci Rep; 2020 Nov; 10(1):20085. PubMed ID: 33208827
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.
Lin HT; Chen CC; Chiao DJ; Chang TY; Chen XA; Young JJ; Kuo SC
Int J Biol Macromol; 2021 Dec; 193(Pt B):1885-1897. PubMed ID: 34774590
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
19. Kappa-RBD produced by glycoengineered Pichia pastoris elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants.
Mi T; Wang T; Xu H; Sun P; Hou X; Zhang X; Ke Q; Liu J; Hu S; Wu J; Liu B
Virology; 2022 Apr; 569():56-63. PubMed ID: 35276485
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]